H.C. Wainwright analyst Robert Burns reiterated a Buy rating on TCR2 Therapeutics (NASDAQ:TCRR) Inc on Friday, setting a price target of $37, which is approximately 32.14% above the present share price of $28.
Burns expects TCR2 Therapeutics Inc to post earnings per share (EPS) of -$0.56 for the first quarter of 2021.
The current consensus among 6 TipRanks analysts is for a Strong Buy rating of shares in TCR2 Therapeutics, with an average price target of $48.33.
The analysts price targets range from a high of $57 to a low of $34.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $0 and a net profit of -$17.19 million. The company's market cap is $1.06 billion.
According to TipRanks.com, H.C. Wainwright analyst Robert Burns is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 34.3% and a 62.60% success rate.
TCR2 Therapeutics, Inc. is an immunotherapy company, which develops biological drugs and engineering T-cells for cancer therapy. The company offers cancer therapy, T-cell biology, Immunology and Molecular biology. It also engages in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded in May 2015 and is headquartered in Cambridge, MA.